Premium
Serum calprotectin (S100A8/A9) levels as a new potential biomarker of treatment response in Hodgkin lymphoma
Author(s) -
Şumnu Şeyma,
Mehtap Özgür,
Mersin Sinan,
Toptaş Tayfur,
Görür Gözde,
Gedük Ayfer,
Ünal Serkan,
Polat Merve Gökçen,
Aygün Kemal,
Yenihayat Emel Merve,
Albayrak Hayrunnisa,
Uluköylü Mengüç Meral,
Tarkun Pınar,
Hacıhanifioğlu Abdullah
Publication year - 2021
Publication title -
international journal of laboratory hematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.705
H-Index - 55
eISSN - 1751-553X
pISSN - 1751-5521
DOI - 10.1111/ijlh.13559
Subject(s) - calprotectin , s100a8 , medicine , biomarker , gastroenterology , lymphoma , inflammation , pathogenesis , chemistry , biochemistry , inflammatory bowel disease , disease
Hodgkin lymphoma (HL) is unusual among malignancies, with inflammation playing such a prominent role in its pathogenesis. S100A8/A9 (calprotectin) is a heterodimeric protein, which has a role in the inflammatory response and oncogenesis. In this study in HL patients, the correlation between serum S100A8/A9 levels and treatment responses was investigated along with whether this marker is correlated with other inflammatory markers. Materials and Methods Thirty‐three HL patients and 20 healthy volunteers were included. Demographic and clinical characteristics were recorded. Calprotectin levels were measured with Human S100A8/A9 Heterodimer Quantikine ELISA kit. Calprotectin levels were measured twice in patients, before and after treatment, and once in the control group. Treatment responses were evaluated with positron emission tomography‐computed tomography (PET‐CT). Results The mean age of patients was 44.3 ± 18.1 (66.3% male). The median (IQR) values of S100A8/A9 before and after treatment in the patient group were 4.98 (2.6‐7.8) and 1.87 (1.1‐4.8)µg/mL. Median (IQR) S100A8/A9 concentration in the control group was 1.41 (0.98‐2.73)µg/mL. In patients, pretreatment values were significantly higher than in controls ( P < .001). However, median values of patients after treatment and controls were similar. Patient median S100A8/A9 levels were significantly lower post‐treatment compared with pretreatment values ( P = .001). When inflammatory markers were examined within groups, no relationship was found between markers. In ROC analysis, a S100A8/A9 cutoff value of ≥3.31µg/mL accurately discriminated end‐of‐treatment PET positivity (AUC = 0.78; 95% CI 0.58‐0.98; accuracy = 76.2%). Conclusion S100A8/A9 may be a potential biomarker for treatment response in HL independent of inflammation. This is the first study to investigate and show this finding. However, further large‐scale studies are still required.